Article
Genetic markers in CYP2C19 and CYP2B6 for prediction of cyclophosphamide's 4-hydroxylation, efficacy and side effects in Chinese patients with systemic lupus erythematosus.
British journal of clinical pharmacology - 1 Feb 2016
Shu Wenying, Guan Su, Yang Xiuyan, Liang Liuqin, Li Jiali, Chen Zhuojia, Zhang Yu, Chen Lingyan, Wang Xueding, Huang Min
Abstract excerpt
AIMS: The aim of the study was to investigate the combined impact of genetic polymorphisms in key pharmacokinetic genes on plasma concentrations and clinical outcomes of cyclophosphamide (CPA) in Chinese patients with systemic lupus erythematosus (SLE). METHODS: One hundred and eighty nine Chinese SLE patients treated with CPA induction therapy (200 mg, every other day) were recruited and adverse reactions were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.